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 Yangyang  Li ,  MS ;  Haijun  Tian ,  PhD ; and  Kangho  Suh ,  PharmD 
 BACKGROUND:  The morbidity and mortality associated with COPD exacts a considerable 
economic burden. Comorbidities in COPD are associated with poor health outcomes and 
increased costs. Our objective was to assess the impact of comorbidities on COPD-associated 
costs in a large administrative claims dataset. 
 METHODS:  This was a retrospective observational study of data from the Truven Health 
MarketScan Commercial Claims and Encounters and the MarketScan Medicare Supplemental 
Databases from January 1, 2009, to September 30, 2012. Resource consumption was measured 
from the index date (date of fi rst occurrence of non-rule-out COPD diagnosis) to 360 days 
aft er the index date. Resource use (all-cause and disease-specifi c [ie, COPD- or asthma-related] 
ED visits, hospitalizations, offi  ce visits, other outpatient visits, and total length of hospital stay) 
and health-care costs (all-cause and disease-specifi c costs for ED visits, hospitalizations, offi  ce 
visits, and other outpatient visits and medical, prescription, and total health-care costs) were 
assessed. Generalized linear models were used to evaluate the impact of comorbidities on total 
health-care costs, adjusting for age, sex, geographic location, baseline health-care use, employ-
ment status, and index COPD medication. 
 RESULTS:  Among 183,681 patients with COPD, the most common comorbidities were car-
diovascular disease (34.8%), diabetes (22.8%), asthma (14.7%), and anemia (14.2%). Most 
patients (52.8%) had one or two comorbidities of interest. Th e average all-cause total health-
care costs from the index date to 360 days aft er the index date were highest for patients with 
chronic kidney disease ($41,288) and anemia ($38,870). Th e impact on total health-care costs 
was greatest for anemia ($10,762 more, on average, than a patient with COPD without anemia). 
 CONCLUSIONS:  Our analysis demonstrated that high resource use and costs were associated 
with COPD and multiple comorbidities.  CHEST 2015; 148(1): 138 - 150 
 [    Original Research  COPD    ] 
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roid; LABA  5 long-acting  b 2 -adrenergic agonist; LAMA  5 long-acting 
muscarinic antagonist; MI  5 myocardial infarction 
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 COPD is defined by GOLD (Global Initiative for 
Chronic Obstructive Lung Disease) as a common, pre-
ventable, and treatable airfl ow limitation disease that is 
usually progressive and is associated with enhanced 
infl ammation in the airways and lungs. 1 COPD results 
in substantial economic burden and mortality. In 2010, 
the projected annual cost of COPD in the United States, 
as determined by the National Heart, Lung, and Blood 
Institute, was $49.9 billion, which included $29.5 billion 
in direct medical costs, $8.0 billion in indirect mor-
bidity costs (eg, lost productivity because of illness), and 
$12.4 billion in indirect mortality costs (eg, lost produc-
tivity because of early death). 2 COPD, together with 
other chronic lower respiratory diseases, is the third 
leading cause of death in the United States. 3 
 Comorbidities are a major determinant of health 
status, health expenditure, and prognosis in patients 
with COPD. 1,4 Patients with COPD with comorbidities 
have poorer health outcomes than those without 
comorbidities. In an analysis of 20,296 patients, poorer 
lung function was associated with having comorbid 
diseases, and those with poorer lung function and 
comorbid diseases had higher risks of morbidity and 
mortality. 4 Worsening of comorbid diseases may be 
related to the airfl ow limitation associated with COPD, 
which can aff ect cardiac function and gas exchange. 1,5 
Proinfl ammatory molecules associated with COPD 
may also contribute to skeletal muscle wasting and 
cachexia and may trigger or exacerbate comorbid heart 
disease, osteoporosis, anemia, diabetes and metabolic 
syndrome, normocytic anemia, and depression. 1,5 
Comorbidities in patients with COPD impose a sub-
stantial economic burden; data across seven countries 
showed that annual societal costs were higher in 
patients with COPD who reported comorbidities than 
in those who did not. 6 
 Th e presence of comorbidities is one of the components 
of the evaluation of a patient with new or suspected 
COPD. 1 Management of patients with COPD includes 
the diagnosis and treatment of comorbidities; however, 
treatment of COPD is generally not aff ected by comor-
bidities, and comorbidities should be treated as if the 
patient did not have COPD. 1 Th e objectives of this study 
were to assess and quantify the impact of comorbidities 
on the costs associated with COPD in a large adminis-
trative claims dataset. 
 Materials and Methods 
 Study Design 
 Th is was a retrospective observational study. Data sources were the 
Truven Health MarketScan Commercial Claims and Encounters and the 
MarketScan Medicare Supplemental Databases from January 1, 2009, to 
September 30, 2012. Records of patients with a COPD diagnosis at any 
diagnosis position within the intake period from July 1, 2009, through 
September 30, 2011, were included. Claims for laboratory, pathology, or 
radiology services were not used to identify individuals with a specifi c 
condition, because their use could incorrectly identify individuals as hav-
ing that condition based on the reason for testing (eg, screening) rather 
than the test results; therefore, those claims were ignored during patient 
selection, and diagnoses were termed non-rule-out COPD. Th e fi rst 
occurrence of non-rule-out COPD diagnosis ( International Classifi cation 
of Diseases, Ninth Revision, Clinical Modifi cation codes 490.xx, 491.xx, 
492.xx, 494.xx, or 496.xx) ( e-Table 1 ) was defi ned as the index event, and the 
date of the index event was defi ned as the index date. None of the source 
databases contained any personal identifi ers. Institutional review board 
approval was not required for this study. Th e study proposal was pre-
sented to and accepted by the Novartis Outcomes Research Review Forum. 
 Patients 
 Eligible patients were aged 40 to 90 years (inclusive), had COPD, and 
used at least one long-acting muscarinic antagonist (LAMA), long-acting 
 b 2 -adrenergic agonist (LABA), inhaled corticosteroid (ICS)/LABA, or 
LAMA  1 ICS  1 LABA from 180 days before the index date through 
180 days aft er the index date. Patients were enrolled continuously in 
the medical, pharmacy benefi t, and fee-for-service plan from 180 days 
before the index date to 360 days aft er the index date. Patients were 
excluded if region information was missing. 
 Variables 
 Comorbidities were defi ned as any occurrence of a specifi c diagnosis 
code from 180 days before the index date through 180 days aft er the 
index date. Th is time period, which does not fall completely within the 
baseline period or the 360-day follow-up period, was chosen to estab-
lish and solidify the baseline patient comorbidities being evaluated. 
Comorbidities of interest were identifi ed prospectively and consisted of 
chronic kidney disease (CKD); cardiovascular disease (CVD), includ-
ing heart failure, stroke, acute myocardial infarction (MI), and periph-
eral vascular disease; asthma; depression; diabetes; osteoporosis; and 
anemia. Resource consumption was measured from 180 days prior to 
the index date to the index date (for baseline assessments) and from the 
index date through 360 days aft er the index date (for outcomes assess-
ments). Resource use assessments included all-cause and disease-
specifi c ED visits, hospitalizations, offi  ce visits (defi ned as any offi  ce 
visit to any doctor), outpatient visits, and total length of hospital stay; 
in this instance, disease-specifi c means COPD- or asthma-related. Th e 
health-care costs assessed included all-cause and disease-specifi c costs 
for ED visits, hospitalizations, offi  ce visits, and other outpatient visits, as 
well as medical, prescription drug, and total health-care costs. All costs 
were adjusted to 2012 US dollars. Other covariate variables included 
age, sex, region, employment status, and index medication (the fi rst 
drug class used during the period). 
 Data Analysis 
 Patient characteristics, comorbidities of interest, health-care use, and 
costs were summarized descriptively. Data were analyzed descriptively 
by the type and number of comorbidities of interest. 
 A generalized linear model (GLM) was used to evaluate which comor-
bidities drive total costs aft er accounting for patient characteristics in 
the total population. Aft er examining the data, we selected GLMs with 
a log-link and  g distribution to evaluate the incremental all-cause costs, 
adjusting for baseline demographics, resource use, and comorbidities. 7 
To better understand total costs that are potentially attributable to 
comorbidities, the average treatment eff ect (change in the response by 
a change in a covariate) of each comorbidity was calculated by using 
the recycled prediction method. 8 Th e predicted costs for patients with 
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CVD were calculated based on the estimated GLM (with costs as the 
dependent variable) by assuming all patients had CVD (regardless of 
whether they had CVD) while keeping other covariates as they were. 
Th e predicted costs, for which every observation is treated as if it rep-
resents patients without CVD, were obtained in the same manner. 
The average treatment effect was the mean difference in the pre-
dicted costs for the two groups. Th us, we compared two hypotheti-
cal populations (one with CVD and one without CVD) that had the 
exact same values for the other independent variables in the model. 
CIs were generated with the percentile method (the 95% lower bound 
CI is the 2.5th percentile of the bootstrap distribution, and the 
95% upper bound CI is the 97.5th percentile of the bootstrap dis-
tribution). Analyses were carried out using SAS version 9.2 (SAS 
Institute).  
 Results 
 Patients 
 Th is analysis included 183,681 patients  ( Fig 1 ). Patient 
characteristics on the index date are summarized in 
 Table 1 , and health-care use and costs from the 180 days 
preceding the index date through the index date are 
summarized in  Table 2 . Th e most common comorbidity 
was CVD (34.8%), followed by diabetes (22.8%), 
asthma (14.7%), anemia (14.2%), CKD (9.9%), depres-
sion (9.9%), and osteoporosis (6.9%). Most patients 
(52.8%) had one or two comorbidities of interest. 
Patients with CKD and anemia experienced the highest 
incidence of all-cause ED visits leading to hospitali-
zations (23.2% and 20.4%, respectively) and all-cause 
hospitalizations (38.0% and 33.8%, respectively). Th e 
percentages of all-cause offi  ce visits and of all-cause 
other outpatient visits were generally similar across 
the various comorbidity groups (all-cause offi  ce visits, 
93.8%-95.4%; all-cause other outpatient visits, 
95.1%-97.7%) and were higher than those for patients 
with no baseline comorbidities of interest (83.9% and 
84.6%, respectively). 
 Th e prevalence of COPD- or asthma-related hospitaliza-
tions was highest among patients with asthma at base-
line (8.3%); for the other baseline comorbidities, the 
frequencies of COPD- or asthma-related hospitaliza-
tions were similar, ranging from 3.4% (osteoporosis) to 
3.9% (depression). Mean all-cause total health-care 
costs from the 180 days before the index date through 
the index date  were highest among patients with CKD 
($19,405) and anemia ($18,011) and lowest among 
those with asthma ($10,583) and osteoporosis ($11,438). 
Mean COPD- or asthma-related total health-care costs 
were highest among patients with asthma ($1,845) and 
osteoporosis ($1,566). 
 In addition to those shown in  Table 2 , analyses were 
conducted based on the number of comorbidities pre-
sent. Patients with four or more comorbidities experi-
enced the highest incidence of ED visits leading to 
hospitalizations (33.1%), compared with 22.2% in those 
with three comorbidities, 13.8% in those with two 
comorbidities, 7.4% in those with one comorbidity, and 
2.5% in those with no comorbidities. Similarly, the rate 
of all-cause hospitalizations was highest in patients with 
four or more comorbidities (50.4%) and lowest in those 
with no comorbidities (5.0%). All-cause total health-
care costs increased as the number of comorbidities 
increased (zero comorbidities of interest, $4,790; four 
or more comorbidities of interest, $27,895), as did 
COPD- or asthma-related total health-care costs (zero 
comorbidity of interest, $871; four or more comorbidities 
of interest, $2,216). 
 Postindex Resource Use and Costs by 
Comorbidities 
 During the time period from the index date through 
360 days aft er the index date, 38.6% of patients with 
COPD and CKD and 34.3% of patients with COPD and 
anemia had all-cause ED visits leading to hospitalizations 
 ( Fig 2A ). Th e percentage of patients experiencing 
all-cause hospitalizations was highest among those with 
CKD (57.0%) and anemia (52.6%) ( Fig 2A ). Th e per-
centage of patients with COPD- or asthma-related 
 Figure 1 – Patient selection. ICS  5 inhaled corticosteroid; LABA  5 
long-acting  b 2 -adrenergic agonist; LAMA  5 long-acting muscarinic 
antagonist. 
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hospitalizations was highest among those with 
asthma (17.4%) and CVD (12.0%) ( Fig 2A ). All-cause 
total health-care costs during the time period from the 
index date through 360 days following the index date 
were highest among patients with COPD and CKD 
($41,288) and patients with COPD and anemia ($38,870) 
( Table 3 ). COPD- or asthma-related total health-care 
costs were highest among patients with COPD and 
asthma ($5,389) and those with COPD and CKD ($5,117). 
 Patients with four or more comorbidities of interest 
experienced the highest incidence of ED visits leading to 
hospitalizations (50.1% vs 9.5% with no comorbidities) 
and all-cause hospitalizations (68.7% vs 16.7% with no 
comorbidities) ( Fig 2B ). All-cause total health-care 
costs and COPD- or asthma-related total health-care 
costs both increased as the number of comorbidities 
increased  ( Table 3 ) . 
 Model Results 
 Th e reference group selected for the GLM was female 
patients with COPD aged 40 to 64 years, living in the 
South, employed, having an index medication of 
ICS/LABA fi xed or loose-dose combination with no 
ED visits or hospitalizations regardless of relationship 
to asthma or COPD, and who did not have CKD, CVD, 
asthma, depression, diabetes, osteoporosis, or anemia. 
In this group, the average total health-care cost was 
$12,408. A ratio, based on the impact on total health-
care costs, was estimated for each variable in the model 
( Table 4 ) and represents multiplicative eff ects. 
 Characteristics with the greatest impact on costs 
included depression (ratio, 1.35), CKD (ratio, 1.43), 
anemia (ratio, 1.54), and CVD (ratio, 1.55) comorbidi-
ties ( Table 4 ). Th e average treatment eff ect for each 
comorbidity aft er adjusting for age, sex, geographic 
location, baseline health-care use, employment status, 
and index COPD medication is shown in  Figure 3 . For 
the time period from the index date through 360 days 
following the index date, a patient with COPD and 
anemia had, on average, $10,762 more in total health-
care costs than a patient with COPD but without anemia. 
CVD and CKD increased total health-care costs by 
$9,882 and $8,912, respectively. 
 Discussion 
 Our results were consistent with those of previously 
published work, in that a significant burden of 
comorbidity was associated with COPD, 9 and comor-
bid conditions were associated with incremental 
increases in resource use and health-care costs. 10,11 Total 
 144  Original Research  [   1 4 8  #  1   C H E S T   J U LY   2 0 1 5   ] 
  TA
B
LE
 2
   ]
     B
as
el
in
e 
Re
so
ur
ce
 U
se
 a
nd
 C
os
ts
   
Pa
ra
m
et
er
Al
l P
at
ie
nt
s 
(N
  5
  18
3,
68
1)
Co
m
or
bi
di
tie
s
CK
D 
(n
  5
  18
,1
81
)
CV
D 
(n
  5
  64
,0
11
)
As
th
m
a 
(n
  5
  27
,0
46
)
De
pr
es
si
on
 
(n
  5
  18
,1
02
)
Di
ab
et
es
 
(n
  5
  41
,9
22
)
Os
te
op
or
os
is
 
(n
  5
  12
,6
44
)
An
em
ia
 
(n
  5
  26
,0
33
)
No
 C
om
or
bi
di
ty
 
(n
  5
  64
,2
32
)
R
es
ou
rc
e 
us
e,
  a    
N
o.
 (
%
)
 
A
ll-
ca
us
e 
ED
 v
is
it
s
 
 
Le
ad
in
g 
to
 
  
 
  ho
sp
it
al
iz
at
io
ns
16
,7
67
 
  
  (9
.1
)
4,
21
6 
  
  (2
3.
2)
11
,0
56
 
  
  (1
7.
3)
3,
74
9 
  
  (1
3.
9)
2,
81
3 
  
  (1
5.
5)
5,
87
4 
  
  (1
4.
0)
1,
41
9 
  
  (1
1.
2)
5,
29
9 
  
  (2
0.
4)
1,
61
6 
  
  (2
.5
)
 
 
N
ot
 le
ad
in
g 
to
 
  
 
  ho
sp
it
al
iz
at
io
ns
40
,1
51
 
  
  (2
1.
9)
6,
93
8 
  
  (3
8.
2)
21
,2
02
 
  
  (3
3.
1)
8,
18
1 
  
  (3
0.
2)
6,
00
5 
  
  (3
3.
2)
11
,9
18
 
  
  (2
8.
4)
3,
18
0 
  
  (2
5.
2)
9,
15
5 
  
  (3
5.
2)
7,
56
2 
  
  (1
1.
8)
 
A
ll-
ca
us
e 
  
 
  ho
sp
it
al
iz
at
io
ns
28
,9
63
 
  
  (1
5.
8)
6,
90
5 
  
  (3
8.
0)
18
,7
72
 
  
  (2
9.
3)
5,
76
2 
  
  (2
1.
3)
4,
46
8 
  
  (2
4.
7)
9,
86
0 
  
  (2
3.
5)
2,
35
7 
  
  (1
8.
6)
8,
79
4 
  
  (3
3.
8)
3,
19
6 
  
  (5
.0
)
 
A
ll-
ca
us
e 
oﬃ
  c
e 
vi
si
ts
16
5,
53
3 
  
  (9
0.
1)
17
,3
49
 
  
  (9
5.
4)
60
,0
74
 
  
  (9
3.
8)
25
,5
73
 
  
  (9
4.
6)
17
,0
61
 
  
  (9
4.
2)
39
,7
62
 
  
  (9
4.
8)
11
,9
90
 
  
  (9
4.
8)
24
,7
12
 
  
  (9
4.
9)
53
,8
65
 
  
  (8
3.
9)
 
A
ll-
ca
us
e 
ot
he
r 
  
 
 ou
tp
at
ie
nt
 v
is
it
s
16
8,
29
1 
  
  (9
1.
6)
17
,7
66
 
  
  (9
7.
7)
61
,6
11
 
  
  (9
6.
3)
25
,7
30
 
  
  (9
5.
1)
17
,4
64
 
  
  (9
6.
5)
40
,5
89
 
  
  (9
6.
8)
12
,1
98
 
  
  (9
6.
5)
25
,3
18
 
  
  (9
7.
3)
54
,3
36
 
  
  (8
4.
6)
 
C
O
PD
- 
or
 
  
 
  as
th
m
a-
re
la
te
d 
ED
 v
is
it
s
 
 
Le
ad
in
g 
to
 
  
 
  ho
sp
it
al
iz
at
io
ns
3,
07
1 
  
  (1
.7
)
43
7 
(2
.4
)
1,
59
8 
  
  (2
.5
)
1,
55
2 
  
  (5
.7
)
49
9 
(2
.8
)
1,
01
4 
  
  (2
.4
)
27
9 
(2
.2
)
62
1 
(2
.4
)
33
8 
(0
.5
)
 
 
N
ot
 le
ad
in
g 
to
 
  
 
  ho
sp
it
al
iz
at
io
ns
6,
07
4 
  
  (3
.3
)
82
1 
(4
.5
)
2,
96
7 
  
  (4
.6
)
2,
46
9 
  
  (9
.1
)
95
9 
(5
.3
)
1,
64
2 
  
  (3
.9
)
52
3 
(4
.1
)
1,
19
7 
  
  (4
.6
)
92
3 
(1
.4
)
 
C
O
PD
- 
or
 
  
 
  as
th
m
a-
re
la
te
d 
ho
sp
it
al
iz
at
io
ns
4,
64
5 
  
  (2
.5
)
66
3 
(3
.6
)
2,
43
0 
  
  (3
.8
)
2,
23
6 
  
  (8
.3
)
70
4 
(3
.9
)
1,
50
0 
  
  (3
.6
)
42
4 
(3
.4
)
95
2 
(3
.7
)
54
8 
(0
.9
)
 
C
O
PD
- 
or
 
  
 
  as
th
m
a-
re
la
te
d 
oﬃ
  c
e 
vi
si
ts
43
,5
01
 
  
  (2
3.
7)
4,
44
8 
  
  (2
4.
5)
16
,7
14
 
  
  (2
6.
1)
12
,6
01
 
  
  (4
6.
6)
4,
49
7 
  
  (2
4.
8)
9,
91
3 
  
  (2
3.
6)
3,
99
8 
  
  (3
1.
6)
6,
71
5 
  
  (2
5.
8)
11
,2
82
 
  
  (1
7.
6)
 
C
O
PD
- 
or
 
  
 
  as
th
m
a-
re
la
te
d 
ot
he
r 
ou
tp
at
ie
nt
 
vi
si
ts
50
,4
68
 
  
  (2
7.
5)
5,
80
6 
  
  (3
1.
9)
20
,7
44
 
  
  (3
2.
4)
12
,3
90
 
  
  (4
5.
8)
5,
24
1 
  
  (2
9.
0)
12
,3
85
 
  
  (2
9.
5)
4,
56
5 
  
  (3
6.
1)
8,
57
8 
  
  (3
3.
0)
13
,0
03
 
  
  (2
0.
2)
C
os
ts
, 
m
ea
n 
(S
D
),
  b    
$
 
A
ll-
ca
us
e 
ED
 v
is
it
 c
os
ts
 
 
Le
ad
in
g 
to
 
  
 
  ho
sp
it
al
iz
at
io
n
78
.6
 
  
  (6
33
.9
)
22
8.
6 
  
  (1
,3
94
.1
)
15
4.
8 
  
  (9
49
.8
)
12
0.
3 
  
  (6
40
.0
)
14
8.
4 
  
  (7
80
.2
)
12
3.
1 
  
  (6
77
.4
)
96
.2
 
  
  (5
70
.7
)
19
5.
9 
  
  (1
,2
06
.4
)
18
.8
 (
19
7.
4)
(C
on
tin
ue
d)
 journal.publications.chestnet.org  145 
Pa
ra
m
et
er
Al
l P
at
ie
nt
s 
(N
  5
  18
3,
68
1)
Co
m
or
bi
di
tie
s
CK
D 
(n
  5
  18
,1
81
)
CV
D 
(n
  5
  64
,0
11
)
As
th
m
a 
(n
  5
  27
,0
46
)
De
pr
es
si
on
 
(n
  5
  18
,1
02
)
Di
ab
et
es
 
(n
  5
  41
,9
22
)
Os
te
op
or
os
is
 
(n
  5
  12
,6
44
)
An
em
ia
 
(n
  5
  26
,0
33
)
No
 C
om
or
bi
di
ty
 
(n
  5
  64
,2
32
)
 
 
N
ot
 le
ad
in
g 
to
 
  
 
  ho
sp
it
al
iz
at
io
n
19
3.
2 
  
  (9
64
.5
)
34
2.
9 
  
  (1
,6
28
.5
)
29
4.
1 
  
  (1
,3
00
.8
)
31
1.
8 
  
  (1
,1
57
.7
)
38
4.
2 
  
  (1
,5
82
.0
)
26
1.
2 
  
  (1
,2
93
.2
)
22
1.
4 
  
  (1
,2
51
.2
)
33
4.
9 
  
  (1
,5
03
.8
)
94
.3
 (
55
2.
1)
 
A
ll-
ca
us
e 
  
 
  ho
sp
it
al
iz
at
io
n 
co
st
s
2,
11
3.
1 
  
  (1
5,
09
6.
5)
7,
81
6.
1 
  
  (3
5,
84
9.
2)
4,
61
5.
2 
  
  (2
3,
41
5.
6)
2,
86
6.
2 
  
  (1
7,
70
5.
3)
4,
54
3.
2 
  
  (2
8,
26
9.
4)
3,
65
5.
4 
  
  (2
1,
83
5.
7)
2,
55
8.
7 
  
  (1
8,
00
3.
4)
6,
57
0.
4 
  
  (3
1,
74
9.
0)
35
2.
3 
  
  (3
,6
60
.7
)
 
A
ll-
ca
us
e 
oﬃ
  c
e 
vi
si
t 
  
 
  co
st
s
48
2.
4 
  
  (5
00
.3
)
73
1.
4 
  
  (6
47
.4
)
62
8.
8 
  
  (5
86
.4
)
60
9.
5 
  
  (5
88
.3
)
63
9.
1 
  
  (6
05
.9
)
60
8.
8 
  
  (5
61
.6
)
64
3.
7 
  
  (6
51
.4
)
72
6.
4 
  
  (6
99
.5
)
31
6.
4 
  
  (3
56
.3
)
 
A
ll-
ca
us
e 
ot
he
r 
  
 
  ou
tp
at
ie
nt
 v
is
it
 
co
st
s
3,
84
1.
8 
  
  (1
0,
75
1.
5)
8,
32
1.
2 
  
  (2
2,
22
8.
3)
5,
95
4.
2 
  
  (1
4,
74
8.
3)
4,
09
0.
3 
  
  (9
,5
35
.7
)
5,
88
2.
9 
  
  (1
2,
77
5.
2)
5,
17
0.
4 
  
  (1
3,
70
0.
9)
4,
95
7.
6 
  
  (1
0,
60
0.
9)
8,
05
8.
6 
  
  (2
0,
23
0.
9)
2,
04
5.
1 
  
  (6
,3
86
.2
)
 
A
ll-
ca
us
e 
m
ed
ic
al
 
  
 
  co
st
s 
(E
D
  1
  
ho
sp
it
al
iz
at
io
n 
 1
  
oﬃ
  c
e 
vi
si
ts
  1
  o
th
er
 
ou
tp
at
ie
nt
)
6,
70
9.
1 
  
  (2
0,
15
5.
3)
17
,4
40
.1
 
  
  (4
4,
85
2.
1)
11
,6
47
.1
 
  
  (2
9,
86
0.
0)
7,
99
8.
1 
  
  (2
1,
67
3.
3)
11
,5
97
.8
 
  
  (3
3,
60
4.
4)
9,
81
8.
8 
  
  (2
7,
87
5.
8)
8,
47
7.
5 
  
  (2
3,
26
5.
1)
15
,8
86
.2
 
  
  (4
0,
24
7.
2)
2,
82
6.
9 
  
  (7
,8
23
.3
)
 
A
ll-
ca
us
e 
pr
es
cr
ip
ti
on
 
  
 
  dr
ug
 c
os
ts
2,
63
6.
5 
  
  (3
,7
05
.4
)
3,
67
8.
1 
  
  (4
,2
88
.3
)
3,
11
8.
3 
  
  (4
,5
49
.5
)
2,
84
3.
7 
  
  (3
,5
95
.1
)
3,
42
2.
4 
  
  (6
,0
40
.7
)
3,
55
4.
6 
  
  (4
,7
11
.9
)
3,
28
7.
5 
  
  (4
,5
45
.1
)
3,
44
2.
8 
  
  (4
,6
87
.0
)
1,
97
6.
8 
  
  (2
,8
28
.0
)
 
A
ll-
ca
us
e 
to
ta
l 
  
 
  he
al
th
-c
ar
e 
co
st
s 
(m
ed
ic
al
 
co
st
s  1
  p
re
sc
ri
pt
io
n 
dr
ug
 c
os
ts
)
9,
09
4.
5 
  
  (1
6,
33
0.
1)
19
,4
05
.5
 
  
  (2
9,
52
1.
0)
14
,1
25
.4
 
  
  (2
2,
53
9.
5)
10
,5
83
.2
 
  
  (1
7,
06
6.
6)
14
,2
00
.2
 
  
  (2
2,
67
6.
7)
12
,8
27
.1
 
  
  (2
0,
52
7.
3)
11
,4
37
.6
 
  
  (1
7,
79
8.
1)
18
,0
10
.9
 
  
  (2
8,
05
9.
2)
4,
78
9.
9 
  
  (8
,2
37
.6
)
 
C
O
PD
- 
or
 
  
 
  as
th
m
a-
re
la
te
d 
ED
 v
is
it
 c
os
ts
 
 
Le
ad
in
g 
to
 
  
 
  ho
sp
it
al
iz
at
io
n
11
.5
 
  
  (1
63
.5
)
16
.0
 (
16
1.
9)
17
.2
 (
19
4.
0)
40
.7
 (
32
3.
4)
18
.3
 (
16
2.
2)
15
.4
 (
14
8.
3)
15
.6
 (
16
9.
4)
16
.9
 (
22
6.
4)
3.
2 
(6
1.
7)
 
 
N
ot
 le
ad
in
g 
to
 
  
 
  ho
sp
it
al
iz
at
io
n
20
.0
 
  
  (2
22
.2
)
22
.2
 (
20
2.
0)
25
.3
 (
23
9.
1)
65
.9
 (
41
8.
2)
35
.7
 (
28
6.
3)
21
.9
 (
21
4.
9)
21
.6
 (
19
1.
8)
26
.8
 (
28
2.
5)
8.
0 
(1
32
.9
)
 
C
O
PD
- 
or
 
  
 
  as
th
m
a-
re
la
te
d 
ho
sp
it
al
iz
at
io
n 
co
st
s
19
3.
5 
  
  (2
,6
02
.1
)
34
5.
3 
  
  (4
,6
90
.5
)
31
5.
6 
  
  (3
,7
24
.5
)
69
0.
3 
  
  (5
,0
52
.3
)
33
8.
9 
  
  (3
,2
88
.7
)
29
4.
1 
  
  (3
,4
58
.8
)
28
5.
5 
  
  (2
,7
21
.3
)
34
7.
7 
  
  (4
,4
75
.8
)
50
.1
 
  
  (9
63
.6
)
(C
on
tin
ue
d)
TA
B
LE
 2
 ]
 (
co
nt
in
ue
d)
 146  Original Research  [   1 4 8  #  1   C H E S T   J U LY   2 0 1 5   ] 
Pa
ra
m
et
er
Al
l P
at
ie
nt
s 
(N
  5
  18
3,
68
1)
Co
m
or
bi
di
tie
s
CK
D 
(n
  5
  18
,1
81
)
CV
D 
(n
  5
  64
,0
11
)
As
th
m
a 
(n
  5
  27
,0
46
)
De
pr
es
si
on
 
(n
  5
  18
,1
02
)
Di
ab
et
es
 
(n
  5
  41
,9
22
)
Os
te
op
or
os
is
 
(n
  5
  12
,6
44
)
An
em
ia
 
(n
  5
  26
,0
33
)
No
 C
om
or
bi
di
ty
 
(n
  5
  64
,2
32
)
 
C
O
PD
- 
or
 
  
 
  as
th
m
a-
re
la
te
d 
oﬃ
  c
e 
vi
si
t 
co
st
s
43
.2
 
  
  (1
22
.5
)
47
.9
 (
14
4.
9)
51
.5
 (
14
6.
9)
89
.0
 (
19
3.
2)
52
.1
 (
13
7.
3)
44
.4
 (
15
5.
6)
68
.3
 (
17
7.
2)
53
.3
 
  
 (1
87
.4
)
28
.5
 (
85
.4
)
 
C
O
PD
- 
or
 
  
 
  as
th
m
a-
re
la
te
d 
ot
he
r 
ou
tp
at
ie
nt
 
vi
si
t 
co
st
s
28
1.
5 
  
  (1
,7
10
.5
)
43
1.
4 
  
  (2
,4
43
.7
)
39
9.
3 
  
  (2
,1
73
.8
)
38
7.
9 
  
  (2
,0
94
.4
)
41
6.
7 
  
  (2
,6
33
.2
)
32
7.
5 
  
  (1
,8
60
.5
)
49
7.
6 
  
  (2
,6
74
.8
)
43
8.
0 
  
 (2
,3
08
.1
)
17
9.
1 
  
  (1
,2
69
.1
)
 
C
O
PD
- 
or
 
  
 
  as
th
m
a-
re
la
te
d 
m
ed
ic
al
 
co
st
s 
(E
D
  1
  
ho
sp
it
al
iz
at
io
n 
 1
  
oﬃ
  c
e 
vi
si
ts
  1
  o
th
er
 
ou
tp
at
ie
nt
)
54
9.
7 
  
  (3
,3
34
.8
)
86
2.
7 
  
  (5
,4
95
.9
)
80
8.
9 
  
  (4
,5
80
.3
)
1,
27
3.
8 
  
  (5
,7
75
.2
)
86
1.
7 
  
  (4
,5
23
.4
)
70
3.
3 
  
  (4
,1
95
.8
)
88
8.
4 
  
  (4
,1
81
.6
)
88
2.
7 
  
  (5
,3
15
.2
)
26
9.
0 
  
  (1
,7
12
.9
)
 
C
O
PD
- 
or
 
  
 
  as
th
m
a-
re
la
te
d 
pr
es
cr
ip
ti
on
 d
ru
g 
co
st
s
59
1.
7 
  
  (6
69
.0
)
57
5.
6 
  
  (6
59
.3
)
59
0.
1 
  
  (6
69
.4
)
58
2.
6 
  
  (6
46
.3
)
49
8.
3 
  
  (6
20
.3
)
57
0.
8 
  
  (6
56
.5
)
67
8.
0 
  
  (7
04
.5
)
57
0.
0 
  
  (6
57
.0
)
60
1.
7 
  
  (6
77
.6
)
 
C
O
PD
- 
or
 
  
 
  as
th
m
a-
re
la
te
d 
to
ta
l h
ea
lt
h-
ca
re
 
co
st
s 
(m
ed
ic
al
 
co
st
s  1
  p
re
sc
ri
pt
io
n 
dr
ug
 c
os
ts
)  c
  
1,
13
8.
6 
  
  (3
,1
85
.3
)
1,
42
1.
3 
  
  (4
,4
76
.5
)
1,
39
1.
0 
  
  (4
,1
13
.6
)
1,
84
5.
1 
  
  (5
,1
91
.1
)
1,
35
9.
2 
  
  (4
,5
78
.9
)
1,
26
7.
1 
  
  (3
,7
08
.9
)
1,
56
6.
5 
  
  (4
,3
02
.5
)
1,
44
1.
0 
  
  (4
,6
41
.2
)
87
0.
7 
  
  (1
,9
06
.3
)
 Se
e 
 Ta
bl
e 
1  
le
ge
nd
 fo
r 
ex
pa
ns
io
n 
of
 a
bb
re
vi
at
io
ns
. 
  a  R
es
ou
rc
e 
us
e 
fr
om
 th
e 
in
de
x 
da
te
 (e
xc
lu
si
ve
) t
hr
ou
gh
 1
80
 d
 b
ef
or
e 
th
e 
in
de
x 
da
te
 (i
nc
lu
si
ve
). 
  b  2
01
2 
US
 d
ol
la
rs
. 
  c  T
ho
se
 w
ith
  .
  $1
81
,0
66
.5
6 
in
 to
ta
l c
os
ts
 h
av
e 
be
en
 c
ap
pe
d 
at
 $
18
1,
06
6.
56
. 
TA
B
LE
 2
 ]
 (
co
nt
in
ue
d)
 journal.publications.chestnet.org  147 
health-care costs during the period from the index 
date through 360 days following the index date were 
greatest among patients with COPD and CKD or 
anemia; COPD- or asthma-related total health-care 
costs were greatest among patients with COPD and 
asthma and CKD. Th ese results were driven, in part, by 
high incidences of all-cause ED visits leading to hospi-
talizations among patients with COPD and CKD or 
anemia, and a high incidence of COPD- or asthma-
related hospitalization among patients with COPD 
and asthma. 
 Multivariable analyses adjusted for age, sex, geographic 
location, baseline health-care use, employment status, 
and index COPD medication showed that the eff ect of 
comorbidities on total health-care costs was greatest 
for anemia. Th is fi nding is consistent with the high inci-
dences of all-cause ED visits leading to hospitalizations 
and all-cause hospitalizations among patients with 
COPD and anemia. Substantial treatment eff ects of 
CVD and CKD (about $9,000) are likely attributable, 
in part, to the high incidence (about 50%) of all-cause 
hospitalization in both groups. 
 Figure 2 – A, B, Resource use from index date through 360 d aft er the index date for each outcome. A, By comorbidity. B, By number of comorbidities. 
CKD  5 chronic kidney disease; CVD  5 cardiovascular disease; ER  5 emergency room.  
 TABLE 3  ]  Total Medical Costs by Comorbidity and Number of Comorbidities 
Comorbidity Total All-Cause Health-care Costs Total All-Cause Hospitalization Costs
Total COPD- or Asthma-Related 
Health-care Costs
All Patients 21,752.8 (28,846.3) 5,523.4 (26,365.2) 3,993.5 (7,283.1)
CKD 41,288.4 (43,468.0) 15,817.1 (50,265.7) 5,117.0 (9,467.0)
CVD 31,734.3 (36,115.8) 10,508.1 (38,004.4) 4,996.9 (9,191.6)
Asthma 25,092.5 (30,739.5) 7,314.5 (29,846.2) 5,389.3 (10,379.6)
Depression 31,661.8 (36,407.5) 10,171.5 (39,321.6) 4,802.1 (9,649.0)
Diabetes 29,245.7 (33,987.8) 8,797.6 (35,505.2) 4,304.6 (8,020.2)
Osteoporosis 26,084.1 (30,715.4) 6,283.6 (26,798.3) 4,995.5 (9,195.7)
Anemia 38,870.3 (42,916.3) 14,101.7 (48,623.3) 4,987.0 (9,565.7)
No. of comorbidities
 0 12,978.3 (18,544.5) 1,834.9 (12,398.5) 3,169.2 (5,254.8)
 1 19,535.8 (24,511.6) 4,077.2 (19,861.6) 3,837.1 (6,658.8)
 2 27,648.7 (31,173.8) 7,607.7 (29,582.7) 4,527.2 (7,937.8)
 3 37,991.4 (38,451.0) 12,681.3 (40,038.7) 5,485.0 (9,962.4)
   4 56,641.9 (50,207.4) 26,006.7 (68,846.1) 6,987.6 (13,797.4)
 Data are presented as mean (SD). Costs are from index date through 360 d after the index date and are in 2012 US dollars. See  Table 1 legend for 
expansion of abbreviations. 
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 TABLE 4  ]  Ratios for Variables Included in the 
Generalized Linear Model 
Variable Ratio (95% CI)
 Age group
 40-64 y a …
 65-90 y 0.95 (0.94-0.97)
Sex
 Female a …
 Male 1.04 (1.03-1.06)
Region
 South a …
 Northeast 1 (0.99-1.02)
 North central (Midwest) 0.91 (0.90-0.92)
 West 1.02 (1.01-1.04)
Employment status
 Employee a …
 Other (spouse/child/dependent 
  relation)
1.08 (1.07-1.09)
Index medication class
 ICS/LABA ﬁ xed or loose-dose 
  combination a 
…
 LABAs 1.08 (1.04-1.13)
 LAMAs 1.08 (1.06-1.09)
 ICS/LABA ﬁ xed or loose-dose 
  combination and LAMA
1.22 (1.20-1.25)
Within the period from the index 
  date (exclusive) through 180 d 
before the index date (inclusive)
 No COPD- or asthma-related 
  ED visits a 
…
 Any COPD- or asthma-related 
  ED visits
1.07 (1.04-1.11)
 No COPD- or asthma-related 
  hospitalizations a 
…
 Any COPD- or asthma-related 
  hospitalizations
1.15 (1.10-1.20)
 No COPD- or asthma-related 
  ED visits a 
…
 Any non COPD- or asthma-related 
  ED visits
1.19 (1.17-1.12)
 No COPD- or asthma-related 
  hospitalizations a 
…
 Any non COPD- or asthma-related 
  hospitalizations
1.15 (1.13-1.17)
Comorbidities of interest
 CKD 1.43 (1.40-1.46)
 CVD (stroke, acute MI, peripheral 
  vascular disease)
1.55 (1.53-1.57)
 Asthma 1.15 (1.13-1.17)
 Depression 1.35 (1.33-1.38)
(Continued)
Variable Ratio (95% CI)
 Diabetes 1.23 (1.22-1.25)
 Osteoporosis 1.18 (1.15-1.20)
 Anemia 1.54 (1.52-1.57)
 Arithmetic mean cost for the reference group was $12,408. See  Table 1 
legend for expansion of abbreviations. 
 a Reference group. 
TABLE 4 ] (continued)
 Cavailles et al 12 reviewed the pathophysiologic and epi-
demiologic links between COPD and the comorbidities 
studied here, and concluded that shared risk factors 
and the infl uence of chronic systemic infl ammation are 
likely contributors to these relationships. Smoking is a 
major risk factor for both COPD and CVD, and CVD 
was the most common comorbidity in the COPD popu-
lation; thus, the frequent coexistence of these two con-
ditions is unsurprising. However, the literature also 
suggests that the systemic infl ammation associated with 
COPD produces a “procoagulant state” and endothelial 
dysfunction that may contribute to thromboembolic 
events. 12 In fact, at least one study 13 has shown that the 
link between cardiovascular events (including death) 
and COPD is independent of smoking status and other 
confounding coronary risk factors. 
 Th ere is no evidence of a direct role for COPD-related 
infl ammation in anemia, 12 which was identifi ed as the 
most costly of the comorbidities in this study. However, 
older age, malnutrition, and CVD frequently accom-
pany COPD and are believed to play a role in the devel-
opment of anemia in patients with COPD. 12 Consistent 
with our fi ndings, Ornek et al 14 determined that anemia 
signifi cantly increased the cost of COPD treatment in 
patients hospitalized for acute exacerbation of COPD. 
Furthermore, anemia was independently prognostic 
for premature mortality, hospital admissions, and 
 Figure 3 – Diff erence in average total health-care cost by comorbidity 
from index date through 360 d aft er the index date in 2012 US dollars. 
See  Figure 2 legend for expansion of abbreviations.  
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cumulative duration of hospitalization in patients with 
severe COPD receiving long-term oxygen therapy. 15 
 Our results support CKD as a key driver of total health-
care costs as well as COPD- and asthma-related health-
care costs in patients with COPD, although it was not as 
prevalent as other comorbidities studied. Epidemiologic 
studies have confirmed COPD as a risk factor for 
CKD, 9,16,17 and the literature suggests that renal function 
is sensitive to hypoxemia and hypercarbia. 18 Addition-
ally, arterial stiff ness associated with COPD may damage 
glomeruli, 18 and some COPD medications may have 
nephrotoxic eff ects. 16 Th e presence of chronic renal 
failure signifi cantly increased the cost of care in patients 
hospitalized for acute exacerbation of COPD. 14 
 Finally, COPD- or asthma-related total health-care costs 
were higher among patients with COPD and asthma 
than among those with any other comorbidity. “Overlap 
syndrome” refers to patients who have components of 
both conditions, and it is oft en used to describe elderly 
individuals in whom the distinction between asthma 
and COPD is diffi  cult to make. 19 In a study of nearly 
25,000 insured adults with COPD, those with asthma 
had 1.6 times greater odds of having respiratory-related 
ED visits, hospitalizations, or both than did those with 
COPD alone and demonstrated an approximately 
50% increase in respiratory-related health-care costs. 20 
 Hospital cost use for COPD or bronchiectasis was 
also evaluated in a recent analysis of the Nationwide 
Inpatient Sample and the Nationwide Emergency 
Department Sample database of the Healthcare Cost and 
Utilization Project. Although signifi cant trends were 
not found in age-adjusted rates of hospital discharges 
from 2001 to 2012, ED visits from 2006 to 2011, or 30-day 
readmissions from 2009 to 2012, the mean charges and 
costs of all discharges increased considerably from 
2001 to 2012, with aggregate charges for inpatient stays 
increasing from $8,023,983,422 in 2001 to $18,112,392,566 
in 2012. 21 
 Th is study was subject to several limitations. Because it 
was restricted to patients who were on long-acting ther-
apies, patients with the mildest form of COPD and 
patients with more advanced disease who were not 
appropriately prescribed long-acting therapies were 
likely excluded. Inherent to claims data research, the 
clinical accuracy of the coding could not be assessed. In 
addition, patients with health maintenance organizations 
or full or partial capitated point-of-service insurance 
coverage were excluded from this study because the 
fi nancial information for this population was incom-
plete. Further, this analysis did not include patients on 
Medicaid and it contained  , 8% of patients with man-
aged Medicare. No information was available regarding 
the severity of disease and the level of treatment adher-
ence. Finally, the study lacked data regarding indirect 
costs related to COPD and comorbidities. An analysis in 
the younger, working-age COPD population (45-64 years 
of age) showed that these costs (which include the 
costs of impaired productivity at work, lost productivity 
because of early retirement, disability pensions paid, 
and tax revenue lost) are considerably higher than the 
direct medical cost of COPD. 22 
 Conclusions 
 In conclusion, these results show that a high prevalence 
of patients with COPD and multiple comorbidities have 
associated high resource use and costs, especially within 
the all-cause use category. Optimizing treatment among 
patients with COPD and comorbidities is a challenge. 
Further research on comorbid conditions aff ecting the 
treatment adherence of patients with COPD, COPD 
pathogenic pathways, and worsening overall prognosis 
is necessary to elucidate the role of comorbidities in 
COPD. 
 150  Original Research  [   1 4 8  #  1   C H E S T   J U LY   2 0 1 5   ] 
 Acknowledgments 
 Author contributions: D. M. M. and K. H. 
take responsibility for the integrity and con-
tent of the manuscript, including the data 
and analysis. D. M. M., K. H., T.-C. Y., H. Z., 
Y. L., H. T., and K. S. contributed to the study 
design, data analysis and interpretation, and 
 writing and review of the manuscript . 
 Financial/nonfi nancial disclosures:  Th e 
authors have reported to  CHEST the following 
confl icts of interest: Dr Mannino has received 
honoraria/consulting fees from and served 
on speaker bureaus for GlaxoSmithKline; 
Novartis Pharmaceuticals Corporation; 
Pfi zer, Inc; Boehringer-Ingelheim GmbH; 
AstraZeneca; Forest Laboratories, Inc; 
Merck & Co; and Amgen. Furthermore, he 
has received royalties from UpToDate and is 
on the board of directors of the COPD 
Foundation. Ms Higuchi is an employee of 
Novartis Pharmaceuticals Corporation. Dr Yu 
is an employee and stockholder of Novartis 
Pharmaceuticals Corporation. Ms Zhou is an 
employee of KMK Consulting Inc and 
provides services to Novartis Pharmaceuticals 
Corporation. Ms Li was a contractor for 
Novartis Pharmaceuticals Corporation from 
Beijing Foreign Enterprises Human Resources 
Services Co, Ltd when the study was conducted. 
Dr Tian is an employee and stockholder of 
Novartis Pharmaceuticals Corporation. 
Dr Suh was an outcomes research fellow of 
Novartis Pharmaceuticals Corporation when 
the study was conducted . 
 Role of sponsors :  Th e sponsor had no role 
in the design of the study, the collection and 
analysis of the data, or the preparation of the 
manuscript. 
 Other contributions: Medical writing services 
were provided by Anny Wu, PharmD, and 
Erica Wehner, RPh, at Complete Healthcare 
Communications, Inc (Chadds Ford, PA), 
with funding from Novartis Pharmaceuticals 
Corporation (East Hanover, NJ). 
 Additional information:  Th e e-Table can be 
found in the Supplemental Materials section 
of the online article. 
 References 
  1 . Global strategy for the diagnosis, man-
agement, and prevention of chronic 
obstructive pulmonary disease. Global 
Initiative for Chronic Obstructive Lung 
Disease website.  http://www.goldcopd.org/
guidelines-global-strategy-for-diagnosis-
management.html . Published  2013 . 
Accessed September 26, 2013. 
  2 . Trends in COPD (chronic bronchitis and 
emphysema): morbidity and mortality. 
American Lung Association website. 
 http://www.lung.org/fi nding-cures/
our-research/trend-reports/copd-trend-
report.pdf . Published  2013 . Accessed 
September 26, 2013. 
  3 .  Hoyert  DL ,  Xu  J .  Deaths: preliminary 
data for 2011 .  Natl Vital Stat Rep .  2012 ;
 61 ( 6 ): 1 - 51 . 
  4 .  Mannino  DM ,  Th orn  D ,  Swensen  A , 
 Holguin  F .  Prevalence and outcomes 
of diabetes, hypertension and cardio-
vascular disease in COPD .  Eur Respir J . 
 2008 ; 32 ( 4 ): 962 - 969 .  
  5 .  Barnes  PJ ,  Celli  BR .  Systemic manifesta-
tions and comorbidities of COPD . 
 Eur Respir J .  2009 ; 33 ( 5 ): 1165 - 1185 .  
  6 .  Wouters  EF .  Economic analysis of the 
Confronting COPD survey: an overview 
of results .  Respir Med .  2003 ; 97 ( suppl C ):
 S3 - S14 .  
  7 .  Deb  P ,  Manning  WG ,  Norton  EC . 
Modeling health care costs and counts. 
Paper presented at: iHEA World Congress; 
July 7-10, 2013; Sidney, Australia .  http://
harrisschool.uchicago.edu/sites/default/
fi les/iHEA_Sydney_minicourse.pdf . 
Accessed August 1, 2013. 
  8 .  Williams  R .  Using the margins com-
mand to estimate and interpret adjusted 
predictions and marginal eff ects .  Stata J . 
 2012 ; 12 ( 2 ): 308 - 331 . 
  9 .  Baty  F ,  Putora  PM ,  Isenring  B ,  Blum  T , 
 Brutsche  M .  Comorbidities and burden 
of COPD: a population based case-control 
study .  PLoS One .  2013 ; 8 ( 5 ): e63285 .  
  10 .  Lin  PJ ,  Shaya  FT ,  Scharf  SM .  Economic 
implications of comorbid conditions 
among Medicaid benefi ciaries with 
COPD .  Respir Med .  2010 ; 104 ( 5 ): 697 - 704 . 
  11 .  Simon-Tuval  T ,  Scharf  SM ,  Maimon  N , 
 Bernhard-Scharf  BJ ,  Reuveni  H ,  Tarasiuk 
 A .  Determinants of elevated healthcare 
utilization in patients with COPD .  Respir 
Res .  2011 ; 12 : 7 .  
  12 .  Cavailles  A ,  Brinchault-Rabin  G ,  Dixmier 
 A ,  et al.  Comorbidities of COPD .  Eur 
Respir Rev .  2013 ; 22 ( 130 ): 454 - 475 . 
  13 .  Sin  DD ,  Man  SF .  Chronic obstructive 
pulmonary disease as a risk factor for 
cardiovascular morbidity and mortality . 
 Proc Am Th orac Soc .  2005 ; 2 ( 1 ):
 8 - 11 .  
  14 .  Ornek  T ,  Tor  M ,  Altın  R ,  et al .  Clinical 
factors affecting the direct cost of 
patients hospitalized with acute exacer-
bation of chronic obstructive pulmonary 
disease .  Int J Med Sci .  2012 ; 9 ( 4 ):
 285 - 290 .  
  15 .  Chambellan  A ,  Chailleux  E ,  Similowski  T ; 
 ANTADIR Observatory Group .  Prog-
nostic value of the hematocrit in patients 
with severe COPD receiving long-term 
oxygen therapy .  Chest .  2005 ; 128 ( 3 ):
 1201 - 1208 .  
  16 .  Mapel  DW ,  Marton  JP .  Prevalence of 
renal and hepatobiliary disease, labora-
tory abnormalities, and potentially toxic 
medication exposures among persons 
with COPD .  Int J Chron Obstruct Pulmon 
Dis .  2013 ; 8 : 127 - 134 .  
  17 .  van Gestel  YR ,  Chonchol  M ,  Hoeks  SE , 
 et al.  Association between chronic 
obstructive pulmonary disease and 
chronic kidney disease in vascular sur-
gery patients .  Nephrol Dial Transplant . 
 2009 ; 24 ( 9 ): 2763 - 2767 . 
  18 .  Mapel  D .  Renal and hepatobiliary dys-
function in chronic obstructive pul-
monary disease .  Curr Opin Pulm Med . 
 2014 ; 20 ( 2 ): 186 - 193 . 
  19 .  Nakawah  MO ,  Hawkins  C ,  Barbandi  F . 
 Asthma, chronic obstructive pulmo-
nary disease (COPD), and the overlap 
syndrome .  J Am Board Fam Med .  2013 ;
 26 ( 4 ): 470 - 477 .  
  20 .  Blanchette  CM ,  Broder  M ,  Ory  C ,  Chang 
 E ,  Akazawa  M ,  Dalal  AA .  Cost and uti-
lization of COPD and asthma among 
insured adults in the US .  Curr Med Res 
Opin .  2009 ; 25 ( 6 ): 1385 - 1392 .  
  21 .  Ford  ES .  Hospital discharges, readmis-
sions, and ED visits for COPD or bron-
chiectasis among US adults: fi ndings 
from the Nationwide Inpatient Sample 
2001-2012 and Nationwide Emergency 
Department Sample 2006-2011 .  Chest . 
 2015 ; 147 ( 4 ):989-998. 
  22 .  van Boven  JF ,  Vegter  S ,  van der Molen 
 T ,  Postma  MJ .  COPD in the working 
age population: the economic impact on 
both patients and government .  COPD . 
 2013 ; 10 ( 6 ): 629 - 639 .  
